Top 10 ASX Dividend Stocks for Sep 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesAnteris Technologies Global Corp. Common Stock

Anteris Technologies Global Corp. Common Stock

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
7.69 USD 0.04 ( 0.52%)
Last update at 2026-09-25T20:00:00Z
VOLUME
762263
Market Cap
812.80M

Momentum Score

…

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.49
Low
7.84
High
52 Week Price Range
3.30
Low
11.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Anteris Technologies Global Corp develops tissue-based cardiovascular implants for heart valve disease. Long-term growth drivers include aging populations increasing valve demand, geographic commercial expansion and its proprietary tissue platform that may support improved durability and biocompatibility.

Material risks include clinical and regulatory execution, strong competition from established medtech firms, limited commercial track record and potential need for additional capital.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.65
Dividend Yield
-
Revenue TTM
2.24M
Revenue Per Share
0.04
Gross Profit TTM
1.68M
Debt / Equity
-24.54
ROE
-74.65%
Net Debt
-10.29M
ROCE
-5797.54%
Diluted EPS TTM
-1.87

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -94.22M -75.97M -46.76M -30.56M -17.17M
Minority interest - - 0.74M 0.00M -
Net income -94.22M -76.29M -46.02M -30.56M -17.17M
Selling general administrative - - 15.96M 14.41M 8.72M
Selling and marketing expenses - - 1.09M 0.81M 0.41M
Gross profit 1.34M 1.27M 0.88M 0.30M 1.91M
Reconciled depreciation - - 1.16M 0.77M 0.64M
Ebit -94.15M -78.37M -46.70M -29.92M -16.14M
Ebitda -92.49M -76.86M -45.54M -29.14M -15.50M
Depreciation and amortization 1.66M 1.51M 1.16M 0.77M 0.64M
Operating income 0.47M -78.37M -48.14M -31.11M -16.86M
Other operating expenses 1.45M 81.08M 50.87M 34.31M 22.69M
Interest expense 0.07M 0.08M 0.07M 0.65M 1.03M
Tax provision - - 0.00M 0.00M 0.00M
Interest income - - 0.43M 0.21M 0.07M
Net interest income - - 0.36M -0.44M -0.97M
Total revenue 1.91M 2.70M 2.73M 3.20M 5.83M
Total operating expenses 0.88M 79.64M 49.02M 31.41M 18.77M
Cost of revenue 0.57M 1.44M 1.86M 2.90M 3.93M
Total other income expense net -94.69M 2.40M 1.38M 0.55M -0.31M
Net income from continuing ops - - -46.76M -30.56M -17.17M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 23.00M 80.70M 30.53M 15.99M 21.43M
Intangible assets 0.07M 0.19M 0.41M 0.61M 0.76M
Other current assets 2.92M 3.30M 0.91M 1.08M 0.89M
Total liab 23.25M 18.02M 11.63M 6.95M 10.91M
Total stockholder equity -0.09M 62.76M 19.30M 9.03M 10.52M
Other current liab 9.70M 9.92M 5.65M 3.81M 4.14M
Common stock 0.00M 0.00M 217.33M 169.79M 141.47M
Capital stock - - 217.33M 169.79M 141.47M
Retained earnings -370.53M -276.39M -200.10M -154.07M -123.51M
Cash 12.58M 70.46M 21.03M 9.29M 15.46M
Total current liabilities 21.37M 16.56M 9.46M 6.05M 10.20M
Net debt -10.29M -69.06M -19.43M -8.34M -11.32M
Short term debt 0.58M 0.75M 0.67M 0.51M 3.83M
Short long term debt - - - - 3.38M
Short long term debt total 2.28M 1.40M 1.60M 0.95M 4.14M
Other stockholder equity 380.71M 350.04M 11.63M 3.26M 0.32M
Total current assets 15.68M 74.65M 24.22M 12.24M 18.75M
Net receivables 0.03M 0.38M 1.85M 1.51M 1.85M
Long term debt - - 0.09M - -
Inventory 0.15M 0.51M 0.44M 0.36M 0.55M
Accounts payable 11.09M 5.89M 3.14M 1.73M 2.23M
Accumulated other comprehensive income -10.28M -10.89M -9.56M -9.94M -7.75M
Non currrent assets other - - 0.42M - -
Non current assets total 7.32M 6.05M 6.31M 3.75M 2.68M
Capital lease obligations - - 1.60M 0.95M 0.76M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - -2.58M -0.99M -0.89M
Total cashflows from investing activities -0.60M -2.28M -2.58M -0.99M -0.89M
Net borrowings - - -0.81M -0.98M 1.74M
Total cash from financing activities 20.55M 112.83M 49.34M 23.27M 27.42M
Net income -94.22M -76.29M -46.76M -30.56M -17.17M
Change in cash -57.88M 49.37M 11.74M -6.10M 12.10M
Begin period cash flow 70.46M 21.09M 9.35M 15.46M 3.35M
End period cash flow 12.58M 70.46M 21.09M 9.35M 15.46M
Total cash from operating activities -77.80M -61.24M -34.63M -29.42M -14.44M
Issuance of capital stock - - 52.82M 25.30M 26.91M
Depreciation 1.66M 1.97M 1.16M 0.77M 0.64M
Other cashflows from investing activities -0.60M -0.01M 0.02M 0.58M -0.00M
Change to inventory 0.36M -0.07M -0.09M 0.19M -0.02M
Change to account receivables -0.52M -0.91M -0.35M -0.53M 0.09M
Other cashflows from financing activities -1.23M 115.07M -2.68M -1.05M -1.23M
Capital expenditures 1.95M 2.27M 2.39M 1.67M 0.58M
Change in working capital 6.26M -0.98M 3.99M -1.75M 0.98M
Stock based compensation 7.78M - 5.76M 2.94M 0.25M
Other non cash items 0.71M 14.06M 1.23M -0.82M 0.86M
Free cash flow -79.76M -63.51M -37.03M -31.08M -15.02M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
AVR
Anteris Technologies Global Corp. Common Stock		 0.04
0.52%		 7.69 - - 362.54 3.38 265.75
ABT
Abbott Laboratories		 0.22
0.22%		 101.29 25.97 17.24 3.57 3.20 3.81
MDT
Medtronic PLC		 0.13
0.15%		 88.64 26.60 15.87 3.35 2.08 3.90
SYK
Stryker Corporation		 2.61
0.97%		 272.36 29.23 16.86 4.18 4.51 4.63
SEMHF
Siemens Healthineers AG		 0.00
0.00%		 43.46 39.57 21.32 3.01 3.29 2.95

Profile*

Anteris Technologies Global Corp. Common Stock

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Toowong Tower, Toowong, QLD, Australia, 4066

61 7 3152 3200

https://anteristech.com

174

Name Title Year Born
Mr. Wayne Geoffrey Paterson Vice Chairman & CEO 1967
Mr. David St. Denis President & Director 1969
Mr. Matthew McDonnell Chief Financial Officer 1974
Dr. Chris Meduri M.D., M.P.H. Chief Medical Officer & Member of Medical Advisory Board NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ATM
AUD 1.06
+8.67%
G6M
AUD 3.49
+7.06%
NST
AUD 23.47
+6.15%
INA
AUD 4.76
+5.78%
MEZ
AUD 4.53
+5.35%
KAR
AUD 1.55
-12.89%
NMG
AUD 0.07
-12.66%
MI6
AUD 0.84
-10.64%
BRE
AUD 3.56
-9.64%
CXO
AUD 0.32
-8.70%

Equity Sectors*

  • Basic Materials

    -2.53%

  • Communication Services

    -0.20%

  • Consumer Cyclical

    -0.30%

  • Consumer Defensive

    -0.14%

  • Energy

    -1.70%

  • Financial Services

    -0.11%

  • Healthcare

    -0.80%

  • Industrials

    -0.68%

  • Real Estate

    +0.72%

  • Technology

    -0.78%

  • Utilities

    +2.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…